China investors energise Hong Kong biotech stocks. Is foreign money missing out?
Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious
Foreign capital, however, remained cautious, analysts said.
“Mainland buyers have been the main force behind the latest healthcare rally. They tend to chase smaller-cap names where a tight free float makes it easier to push prices higher,” said Jonah Chen, head of healthcare research at China Merchants Securities (Hong Kong). “They are also getting excited by a surge in big-ticket out-licensing deals.”
His comments came as at least 13 healthcare companies – including AI-driven drug discovery firm Insilico Medicine, innovative drug maker Xuanzhu Biopharmaceutical, and CARsGen Therapeutics, developer of cutting-edge cancer treatment CAR-T cell therapy – were among 42 stocks added to the southbound list, according to an exchange filing with the Shanghai Stock Exchange.
The southbound leg of Stock Connect allows mainland Chinese investors to buy and sell shares listed in Hong Kong through the Shanghai and Shenzhen exchanges.
